News and Announcements
Actinogen has US Patent Granted and Further Extends Xanamem Protection
- Published July 21, 2016 3:26PM UTC
- Publisher Wholesale Investor
- Categories Company Updates
20th July 2016, ASX Announcement
- United States Patent granted for use of Xanamem™ in Alzheimer’s dementia and other diseases.
- Xanamem™’s long patent life now further extended to 2031 in the US.
- Comprehensive protection over Xanamem™ now received for most major markets.
Actinogen Medical Limited (Actinogen Medical, ASX: ACW), is pleased to announce it has received official notification to grant from the United States Patent Office for the most comprehensive patent for Xanamem. This patent further extends the comprehensive cover for Xanamem through to 2031.
The patent ( US 9,365,654 B2) protects use of Xanamem™ for use in Alzheimer’s dementia and other relate diseases associated with the inhibition of the 11-beta-hydroxysteroid dehydrogenase (11β-HSD1) enzyme. Importantly this patent cover through to 2031 comes on top of previous approvals in most other major markets, including all European countries and the UK, Australia, Japan and China.
To view the full announcement, please click on the button below.
Company Updates
Capital Is Flowing – Just Not to Everyone: Inside Australia’s $1.8 Billion Q1 2026
Australia’s startup ecosystem opened 2026 with a number that demanded attention. In the first three months of the year, $1.8 billion was raised across 81 venture deals and 26 accelerator rounds. That makes Q1 2026 the strongest start to a year since the 2022 boom, up 63% on Q1 2025, and more than double the […]
The control layer for the electrified home
THE MARKET SHIFT Australian households have been pulled into a real-time energy market they never knowingly signed up for. Flat electricity tariffs are disappearing. In their place: dynamic, time-of-use pricing that changes depending on when power is consumed. Electricity is now cheapest when solar floods the grid in the middle of the day — and […]
500 Million Episodes, Limited Treatment: How Patrys is Bridging the Gap in an Underserved Market
In the clinical vocabulary of the Intensive Care Unit, there is perhaps no word that carries as much quiet dread as delirium. It is a “chemical storm” of the brain—an acute dysfunction where the delicate balance between calming and activating signals is scrambled. For the patient, it can be a waking nightmare of hallucinations and […]
Backed By Leading Investment Groups and Family Offices
